α-synuclein aggregation reduces nigral myocyte enhancer Factor-2D in idiopathic and experimental Parkinson's disease

Neurobiology of Disease

Volumn 41, Issue 1, 2011, Pages 71-82

  Chu, Yaping ^a   Mickiewicz, Amanda L ^a   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alpha synuclein; Dopaminergic neuron; Myocyte enhancer factor 2D; Parkinson's disease; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN; MYOCYTE ENHANCER FACTOR 2D; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC DISEASE; IMMUNOREACTIVITY; MALE; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; TRANSCRIPTION REGULATION;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HUMANS; INCLUSION BODIES; MADS DOMAIN PROTEINS; MALE; MIDDLE AGED; MYOGENIC REGULATORY FACTORS; NEURONS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; SUBSTANTIA NIGRA;

EID: 78349309689     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.08.022     Document Type: Article

References (37)

1. Badaut J., Ashwal S., Tone B., Regli L., Tian H.R., Obenaus A. Temporal and regional evolution of Aquaporin-4 expression and magnetic resonance imaging in a rat pup model of neonatal stroke. Pediatr. Res. 2007, 62:248-254.
2. Black B.L., Olson E.N. Transcriptional control of muscle development by myocyte enhancer factor-2 (MEF2) proteins. Annu. Rev. Cell Dev. Biol. 1998, 14:167-196.
3. Borghi S., Molinari S., Razzini G., Parise F., Battini R., Ferrari S. The nuclear localization domain of the MEF2 family of transcription factors shows member-specific features and mediates the nuclear import of histone deacetylase. J. Cell Sci. 2001, 114:4477-4483.
4. Braak H., Del Tredici K., Rüb U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003, 24:197-211.
5. Butts B.D., Hudson H.R., Linseman D.A., Le S.S., Ryan K.R., Bouchard R.J., Heidenreich K.A. Proteasome inhibition elicits a biphasic effect on neuronal apoptosis via differential regulation of pro-survival and pro-apoptotic transcription factors. Mol. Cell. Neurosci. 2005, 30:279-289.
6. Chu Y., Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease?. Neurobiol. Dis. 2007, 25:134-149.
7. Chu Y., Kordower J.H. Lewy body pathology in fetal grafts. Ann. NY Acad. Sci. 2010, 1184:55-67.
8. Chu Y., Le W., Kompoliti K., Jankovic J., Mufson E.J., Kordower J.H. Nurr1 in Parkinson's disease and related disorders. J. Comp. Neurol. 2006, 494:495-514.
9. Chu Y., Dodiya H., Aebischer P., Olanow C.W., Kordower J.H. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol. Dis. 2009, 35:385-398.
10. Dice J.F. perone-mediated autophagy. Autophagy 2007, 3:295-299.
11. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
12. Flavell S.W., Cowan C.W., Kim T.K., Greer P.L., Lin Y., Paradis S., Griffith E.C., Hu L.S., Chen C., Greenberg M.E. Activity-dependent regulation of MEF2 transcription factors suppresses excitatory synapse number. Science 2006, 311:1008-1012.
13. Flavell S.W., Kim T.K., Gray J.M., Harmin D.A., Hemberg M., Hong E.J., Markenscoff-Papadimitriou E., Bear D.M., Greenberg M.E. Genome-wide analysis of MEF2 transcriptional program reveals synaptic target genes and neuronal activity-dependent polyadenylation site selection. Neuron 2008, 60:1022-1038.
14. Giasson B.I., Jakes R., Goedert M., Duda J.E., Leight S., Trojanowski J.Q., Lee V.M. A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res. 2000, 59:528-533.
15. Giasson B.I., Duda J.E., Quinn S.M., Zhang B., Trojanowski J.Q., Lee V.M. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 2002, 34:521-533.
16. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2001, 2:492-501.
17. Haber S.N., Groenewegen H.J. Interrelationship of the distribution of neuropeptides and tyrosine hydroxylase immunoreactivity in the human substantia Nigra. J. Comp. Neurol. 1989, 290:53-68.
18. Heidenreich K.A., Linseman D.A. Myocyte enhancer factor-2 transcription factors in neuronal differentiation and survival. Mol. Neurobiol. 2004, 29:155-166.
19. Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Björklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J. Neurosci. 2002, 22:2780-2791.
20. Kirik D., Annett L.E., Burger C., Muzyczka N., Mandel R.J., Björklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc. Natl Acad. Sci. USA 2003, 100:2884-2889.
21. Li M., Linseman D.A., Allen M.P., Meintzer M.K., Wang X., Laessig T., Wierman M.E., Heidenreich K.A. Myocyte enhancer factor 2A and 2D undergo phosphorylation and caspase-mediated degradation during apoptosis of rat cerebellar granule neurons. J. Neurosci. 2001, 21:6544-6552.
22. Lin X., Shah S., Bulleit R.F. The expression of MEF2 genes is implicated in CNS neuronal differentiation. Mol. Brain Res. 1996, 42:307-316.
23. Maingay M., Romero-Ramos M., Kirik D. Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. C.N.S. Spectr 2005, 10:235-244.
24. Mao Z., Bonni A., Xia F., Nadal-Vicens M., Greenberg M.E. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 1999, 286:785-790.
25. Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
26. Nishioka K., Hayashi S., Farrer M.J., Singleton A.B., Yoshino H., Imai H., Kitami T., Sato K., Kuroda R., Tomiyama H., Mizoguchi K., Murata M., Toda T., Imoto I., Inazawa J., Mizuno Y., Hattori N. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann. Neurol. 2006, 59:298-309.
27. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
28. Recchia A., Debetto P., Negro A., Guidolin D., Skaper S.D., Giusti P. Alpha-synuclein and Parkinson's disease. FASEB J. 2004, 18:617-626.
29. Saha R.N., Ghosh A., Palencia C.A., Fung Y.K., Dudek S.M., Pahan K. TNF-alpha preconditioning protects neurons via neuron-specific up-regulation of CREB-binding protein. J. Immunol. 2009, 183(3):2068-2078.
30. Shalizi A., Gaudillière B., Yuan Z., Stegmüller J., Shirogane T., Ge Q., Tan Y., Schulman B., Harper J.W., Bonni A. A calcium-regulated MEF2 sumoylation switch controls postsynaptic differentiation. Science 2006, 311:1012-1017.
31. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K.S., Selkoe D.J. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science 2001, 293:263-269.
32. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
33. Smith P.D., Mount M.P., Shree R., Callaghan S., Slack R.S., Anisman H., Vincent I., Wang X., Mao Z., Park D.S. Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J. Neurosci. 2006, 26:440-447.
34. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
35. Tang X., Wang X., Gong X., Tong M., Park D., Xia Z., Mao Z. Cyclin-dependent kinase 5 mediates neurotoxin-induced degradation of the transcription factor myocyte enhancer factor 2. J. Neurosci. 2005, 25:4823-4834.
36. Towne C., Raoul C., Schneider B.L., Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: neuromuscular transduction does not alter disease progression in fALS mice. Mol. Ther. 2008, 16:1018-1025.
37. Yang Q., She H., Gearing M., Colla E., Lee M., Shacka J.J., Mao Z. Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 2009, 323:124-127.